Skip to main content
. Author manuscript; available in PMC: 2019 Sep 15.
Published in final edited form as: Neuropharmacology. 2018 Aug 4;140:150–161. doi: 10.1016/j.neuropharm.2018.08.003

FIGURE 6:

FIGURE 6:

Effects of GSK3787, TXNIP CRISPR activation plasmid and antimir-17-5p with GW0742 on infarct volume (A–B) and neurological function (C) at 72 hours post hypoxia-ischemia (HI). (A-B) The infarct volume was significantly increased in all 3 treatment groups with interventions when compared with respective controls treated with GW0742. (C) Negative geotaxis showed that animal groups treated with GW0742 and either GSK3787, TXNIP CRISPR activation plasmid or antimir-17-5p had significantly impaired neurological function compared with respective controls treated with GW0742. *p<0.05 vs. sham; #p < 0.05 vs. HI+vehicle; &p <0.05 vs. HI+GW0742+DMSO in corn oil; @p < 0.05 vs. HI+GW0742+control CRISPR; $p < 0.05 vs. HI+GW0742+control LNA. n = 6 for each group.